drugset / Trial / NCT05806580
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2027-05-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relmacabtagene Autoleucel | Cell therapy | — | — |